ArticleThe journal of allergy and clinical immunology. In practice2026
Oral Food Challenges After Treatment With Omalizumab in the Clinical Setting.
Article in The journal of allergy and clinical immunology. In practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlthough omalizumab is now approved for the treatment of food allergy, little is known about its use in the clinical setting.
objectiveTo examine the outcome of oral food challenges (OFCs) after treatment with omalizumab.
methodsWe conducted a retrospective chart review of clinic patients who underwent OFCs after treatment with omalizumab, including cumulative tolerated doses and all adverse events.
resultsA total of 51 patients (45% female; median age, 9 [range, 1-23] years; median total IgE, 512 [interquartile range, 285 to 1080] IU/mL) underwent 73 OFCs, with milk (n = 27), egg (n = 23), and wheat (n = 9) accounting for 81% of the OFCs. A reaction history was documented for 95% and all challenged foods had a positive allergen-specific IgE (median, 34 [interquartile range, 12 to >100] kUA/L). OFCs were performed at a median of 7 (range, 4-14) months after starting omalizumab. Among OFCs to any food with a goal dose ≥6000 mg (n = 56), 89% successfully consumed ≥1000 mg, 86% ≥2000 mg, 75% ≥4000 mg, and 66% ≥6000 mg. Allergic reactions occurred in 45% (n = 33) of all OFCs, with 21 treated with antihistamines and 2 treated with epinephrine. Dietary introduction of allergenic foods was permitted following 92% of OFCs. Omalizumab treatment response was associated with higher baseline total IgE, every 2-week dosing versus every 4-week dosing, higher total omalizumab dose per 4 weeks per weight, and lower allergen-specific IgE to total IgE ratio.
conclusionsOmalizumab can be effectively used for the treatment of food allergy in the clinical setting and may enable the introduction of allergenic foods into the diet for most patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.